The Market Is Heating Up And REalloys Is On The Right Side

REalloys Inc. received a Buy rating with a $35 price target, implying 77.3% upside by 2030, supported by new supply partners and accelerated execution with SRC. The company targets a heavy rare-earth production ramp beginning in Q4 2026 and has $122M of cash with key projects fully funded. Further equity dilution remains a material risk as the company finances its production scale-up.

Analysis

ALOY is best viewed as a long-dated option on Western heavy-rare-earth qualification rather than a near-term earnings story. Until product specifications, customer offtake terms, recoveries, and unit costs are independently disclosed, the equity will trade primarily on financing and milestone credibility; a strong cash balance reduces near-term solvency risk but does not establish project-level returns. The likely equity overhang is dilution ahead of commercial scale, particularly if capex, working-capital needs, or qualification timelines exceed management assumptions.

The more investable second-order read is that credible non-Chinese heavy-rare-earth supply would validate scarcity pricing across the chain, benefiting established ex-China platforms such as Lynas (LYC.AX/LYSDY) and potentially MP Materials (MP) if U.S. policy support broadens beyond NdPr into dysprosium/terbium. ALOY's progress could also pressure other pre-revenue critical-mineral developers by raising the bar for funded capacity and customer validation. In the next 1-3 months, partnership announcements may support sentiment, but the meaningful rerating catalyst is a binding offtake with pricing floors or government-backed procurement; absent either, the market should discount headline partnerships heavily.

Consensus may be underestimating the distinction between access to feedstock and economically recoverable, specification-grade separated oxides. Heavy rare-earth markets are small and opaque, so incremental supply can face qualification bottlenecks while price assumptions are vulnerable to Chinese export-policy reversals or inventory releases. The structural upside case becomes credible over 6-18 months only if ALOY demonstrates repeatable recoveries at pilot scale, secures customers, and funds construction without materially impairing per-share economics.

Key Decisions for Investors

• Treat ALOY as a small, venture-style watchlist position rather than a core long before Q4 2026: initiate only after disclosure of binding offtake terms, expected annual separated-oxide output, and project capex. Size for a potential 50%+ drawdown given pre-revenue execution and dilution risk.
• For liquid critical-minerals exposure over the next 6-12 months, prefer a basket long LYSDY and MP versus a speculative single-name ALOY position; these names offer more direct exposure to Western supply-chain policy and have clearer operating milestones.
• Set a dilution alert: reassess any ALOY long if cash runway falls below 18 months, share count rises materially without a corresponding funded-capacity increase, or commercial ramp shifts beyond 2027. These outcomes would challenge the per-share value premise even if demand remains strong.
• Use a catalyst-based entry rather than chasing partnership headlines: add only on independently verifiable milestones such as third-party assay results, customer qualification, or fixed-price/minimum-volume contracts. A binding offtake with a credible counterparty is the key event that could justify a multiple expansion.
• Falsify the broader heavy-rare-earth scarcity trade if Chinese export restrictions ease materially, dysprosium/terbium pricing weakens despite policy support, or U.S./allied procurement programs fail to translate into contracted volumes within the next 12 months.